These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26537156)

  • 1. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.
    Mehta H; Fraser-Bell S; Yeung A; Campain A; Lim LL; Quin GJ; McAllister IL; Keane PA; Gillies MC
    Br J Ophthalmol; 2016 Jul; 100(7):1000-1004. PubMed ID: 26537156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial.
    Mehta H; Fraser-Bell S; Nguyen V; Lim LL; Gillies MC
    Ophthalmol Retina; 2018 Mar; 2(3):231-234. PubMed ID: 31047591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
    Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
    Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema.
    Aroney C; Fraser-Bell S; Lamoureux EL; Gillies MC; Lim LL; Fenwick EK
    Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5541-5546. PubMed ID: 27768792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema.
    Wickremasinghe SS; Fraser-Bell S; Alessandrello E; Mehta H; Gillies MC; Lim LL
    Br J Ophthalmol; 2017 Oct; 101(10):1329-1333. PubMed ID: 28228411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
    Totan Y; Güler E; Gürağaç FB
    Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
    Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S
    Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.
    Sharma A; Bellala K; Dongre P; Reddy P
    Int Ophthalmol; 2020 Jan; 40(1):67-72. PubMed ID: 31377905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
    Shin YU; Hong EH; Lim HW; Kang MH; Seong M; Cho H
    BMC Ophthalmol; 2017 Oct; 17(1):182. PubMed ID: 28974211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study.
    Comet A; Gascon P; Ramtohul P; Donnadieu B; Denis D; Matonti F
    Eur J Ophthalmol; 2021 Mar; 31(2):754-758. PubMed ID: 32507032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials.
    Danis RP; Sadda S; Li XY; Cui H; Hashad Y; Whitcup SM
    Br J Ophthalmol; 2016 Jun; 100(6):796-801. PubMed ID: 26581718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
    Arevalo JF; Lasave AF; Wu L; Acon D; Farah ME; Gallego-Pinazo R; Alezzandrini AA; Fortuna V; Quiroz-Mercado H; Salcedo-Villanueva G; Maia M; Serrano M; Rojas S;
    Br J Ophthalmol; 2016 Dec; 100(12):1605-1610. PubMed ID: 26912377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.